"In the pharmaceutical industry, you can have hundreds of patents on a drug" - Tahir Amin

"They had all these patents covering all these variations, different dosages, even different sort of needle sizes on the pens that deliver the drug," says Tahir Amin, I-Mak's CEO.
"All this built up to block-off competition because when you go to litigation, you pay millions of dollars to just remove one patent." The practice known as "evergreening", is criticised by I-Mak and others as a flaw in the patent system that allows corporations to prolong lucrative monopolies.
Read our latest investigation #deadlyprices on how big pharma feeds inequality in Europe: www.investigat...